
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Details : Tenalisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RP7214 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
